Ireland - English - HPRA (Health Products Regulatory Authority)

b & s healthcare - pancreatin - capsule - 150 milligram - enzyme preparations

Ireland - English - HPRA (Health Products Regulatory Authority)

clear pharmacy - rosuvastatin - film coated tablet - 20 milligram - hmg coa reductase inhibitors

Ireland - English - HPRA (Health Products Regulatory Authority)

clear pharmacy - rosuvastatin - film coated tablet - 10 milligram - hmg coa reductase inhibitors

Ireland - English - HPRA (Health Products Regulatory Authority)

merck serono limited - metformin hydrochloride - powder for oral solution - 500 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

pco manufacturing ltd. - esomeprazole - gastro-resistant tablet - 40 milligram(s) - esomeprazole

Ireland - English - HPRA (Health Products Regulatory Authority)

pco manufacturing ltd. - esomeprazole - gastro-resistant tablet - 20 milligram(s) - esomeprazole

Ireland - English - HPRA (Health Products Regulatory Authority)

pco manufacturing ltd. - lisinopril dihydrate - tablet - 20 milligram(s) - ace inhibitors, plain; lisinopril

Malta - English - Medicines Authority

abbott healthcare products limited - pancreatin 300 mg - capsule

United States - English - NLM (National Library of Medicine)

astrazeneca pharmaceuticals lp - bicalutamide (unii: a0z3nau9dp) (bicalutamide - unii:a0z3nau9dp) - bicalutamide 50 mg - casodex 50 mg daily is indicated for use in combination therapy with a luteinizing hormone-releasing hormone (lhrh) analog for the treatment of stage d2 metastatic carcinoma of the prostate. casodex 150 mg daily is not approved for use alone or with other treatments [see clinical studies (14.2)]. casodex is contraindicated in: casodex is contraindicated in any patient who has shown a hypersensitivity reaction to the drug or any of the tablet’s components. hypersensitivity reactions including angioneurotic edema and urticaria have been reported. casodex has no indication for women, and should not be used in this population. casodex can cause fetal harm when administered to a pregnant woman [see use in specific populations (8.1)] . risk summary casodex is contraindicated for use in pregnant women because it can cause fetal harm. casodex is not indicated for use in females. there are no human data on the use of casodex in pregnant women. in animal reproduction studies, oral administration of bicalutamide to p

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

atnahs pharma uk ltd - lisinopril - oral tablet - 5mg